People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo ...

Ozempic and Wegovy have the same active ingredient, semaglutide. Wegovy has been approved by the Food and Drug Administration (FDA) for weight loss. Ozempic has been approved for diabetes, though it's ...

Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Global health highlights include a court pausing a generic version of a heart drug, Novo Nordisk's weight loss trial success, ...

However, a third drug also FDA-approved for weight loss, liraglutide (Saxenda), didn’t work as well as the others, ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for ...